Urol. praxi. 2018;19(3):127-132 | DOI: 10.36290/uro.2018.070

Current options and trends in treating erectile dysfunction

MUDr. Otakar Štanc
Urologická klinika 3. LF UK Fakultní nemocnice Královské Vinohrady, Praha

Erectile dysfunction (ED) is a very frequent disease. The past decades have witnessed a dramatic development in its treatment,associated with an increased interest in this issue by both doctors and patients. The advent of PDE5 inhibitors in the late 1990swas a revolution in treatment. Since then no such fundamental progress has been made; however, evolution in treatment hascontinued up to the present day. This article summarizes the current treatment options for ED and trends in the development ofnew therapies.

Keywords: erectile dysfunction, treatment.

Published: July 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štanc O. Current options and trends in treating erectile dysfunction. Urol. praxi. 2018;19(3):127-132. doi: 10.36290/uro.2018.070.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Weiss P, Zvěřina J. Sexuální chování obyvatelstva ČR IV. Praha: DEMA, 2009.
    2. Lopushnyan NA, Chitaley K. Genetics of erectile dysfunction. Journal of Urology. November 2012; 188(5): 1676-1683. Go to original source... Go to PubMed...
    3. Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. Journal of Sexual Medicine. 2010; 7: 1598-1607. Go to original source... Go to PubMed...
    4. Lue TF. Erectile dysfunction. New England Journal od Medicine. 2000; 324: 1802-1813. Go to original source... Go to PubMed...
    5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. Journal of Urology. 1994; 151(1): 54-61. Go to original source... Go to PubMed...
    6. Valicenti RK, Bissonette EA, Chen C, Theodorescu D. Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. Journal of Urology. 2002; 168(6): 2499-2504. Go to original source... Go to PubMed...
    7. Bryant C, et al. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology. 2016; 95(1): 422-434. Go to original source... Go to PubMed...
    8. Hagberg KW, et al. Impact of 5-alpha reductase inhibitors for treatment of benign prostatic hyperplasia on erectile dysfunction, treated depression, gynecomastia, and breast cancer: A real world 20 year observational study. European Urology 2017; 16(Suppl. 3): e919. Go to original source...
    9. Zámečník L. Praktická andrologie dospělých. Praha: Mladá fronta, 2010.
    10. Liming J, Burnett AL. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and therapeutic insights. Clinical Science. 2006; 110(2): 153-165. Go to original source... Go to PubMed...
    11. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proceedings of National Academy of Science. 2004; 101: 9121-9126. Go to original source... Go to PubMed...
    12. Gratzke C, Strong TD, Gebska MA, Champion HC, Stief CG, Burnett AL, Bivalacqua TJ. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. Journal of Urology. November 2010; 184(5): 2197-2204. Go to original source... Go to PubMed...
    13. Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Burnett AL. Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction. The FASEB Journal. March 2006; 20(3): 536-538. Go to original source... Go to PubMed...
    14. Šrámková T. Psychogenní erektilní dysfunkce. In: Zámečník L. Praktická andrologie dospělých. Praha: Mladá Fronta, 2010.
    15. Pastor Z. Erektilní dysfunkce. Postgraduální medicína. 2011; 13(1): 20-25.
    16. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. Journal of Sexual Medicine. 2006; 3(1): 28-36. Go to original source... Go to PubMed...
    17. Levine GN, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2012; 125(8): 1058-1072. Go to original source... Go to PubMed...
    18. Clavell-Hernández J, Wang R. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion: No. International Brazilian Journal of Urology: official journal of the Brazilian Society of Urology. 2017; 43(3): 390-393. Go to original source... Go to PubMed...
    19. Raina R, Lakin MM, Agarwal A, Sharma R, Goyal KK, Montague DK, et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology. July 2003; 62(1): 110-115. Go to original source... Go to PubMed...
    20. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology. 2007; 177(4): 1401-1407. Go to original source... Go to PubMed...
    21. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International Journal of Clinical Practice. July 2006; 60(7): 762-769. Go to original source... Go to PubMed...
    22. Zhang XH, Melman A, Disanto E. Update on corpus cavernosum smooth muscle contractile pathways in erectile function: a role for testosterone? Journal of Sexual Medicine. 2011; 8(7): 1865-1879. Go to original source... Go to PubMed...
    23. Mulligan T, Frick MF, Zuraw QC, Stemhagen S, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International Journal of Clinical Pracitce. 2006; 60(7): 762-769. Go to original source... Go to PubMed...
    24. Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. Journal of Sexual Medicine. June 2014; 11(6): 1577-1592. Go to original source... Go to PubMed...
    25. Greco EA, Spera G, Aversa A. Combining Testosterone and PDE5 Inhibitors in Erectile Dysfunction: Basic Rationale and Clinical Evidences. European Urology. November 2006; 50(5): 940-947. Go to original source... Go to PubMed...
    26. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Canadian Urological Association Journal. 2016; 6(4): 269-274. Go to original source...
    27. Calogero AE, Aversa A, La Vignera G, et. al. The use of nutraceuticals in male sexual and reproductive disturbances: position statement from the Italian Society. Journal of Endocrinological Investigation. 2017; 40: 1389-1397. Go to original source... Go to PubMed...
    28. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. New England Journal of Medicine. 4. April 1996; 334(14): 873-877. Go to original source... Go to PubMed...
    29. Heráček J, Urban M, Lukeš M, Zachoval R, Záleský M, Bittner L. Intrakavernózní vazoaktivní léčba erektilní dysfunkce. Urologické listy 2006: 4(1).
    30. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. Journal of Urology. March 2008; 179(3): 1066-1071. Go to original source... Go to PubMed...
    31. Gülru K, Nurcan Ş, Durdagi T. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors. Journal of Biomolecular Structure and Dynamics. 2016; 35(13): 2830-2852. Go to original source... Go to PubMed...
    32. Bivalacqua TJ, et al. Attenuated RhoA/Rhokinase signaling in penis of transgenic sickle cell mice. Urology. 2010; 76: 510.e7-510.e12. Go to original source...
    33. Albersen M, Linsen L, Tinel H, Sandner P, Van Renterghem K. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. Journal of Sexual Medicine. May 2013; 10(5): 1268-1277. Go to original source... Go to PubMed...
    34. Decaluwé K, et al. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice. Journal of Sexual Medicine. 2017; 14(2): 196-204. Go to original source... Go to PubMed...
    35. Zámečník L. Genová terapie - nová naděje v léčbě erektilní dysfunkce? Urologické Listy. 2007; 5(3): 34-37.
    36. Király O, Pataricza J, Bajory Z, et al. Involvement of Large-Conductance Ca2+-Activated K+ Channels in both Nitric Oxide and Endothelium-Derived Hyperpolarization-Type Relaxation in Human Penile Small Arteries. Basic and Clinical Pharmacology and Toxicology. 2013; 113(1): 19-24. Go to original source... Go to PubMed...
    37. González-Corrochano R, La Fuente J, Cuevas P, Fenández A, Chen M, Sáenz de Tejada I, Angulo J. Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. British Journal of Pharmacology. 2013; 169(2): 449-461. Go to original source... Go to PubMed...
    38. Christ GJ, Day N, Santizo C, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. American Journal of Physiology-Heart and Circulatory Physiology. 2004; 287: 1544-1553. Go to original source... Go to PubMed...
    39. Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006; 17: 1165-1176. Go to original source...
    40. Ryu JK, Suh JK, Burnett AL. Research in pharmacotherapy for erectile dysfunction. Translational Andrology and Urology. 2017; 6(2): 207-215. Go to original source... Go to PubMed...
    41. Kwon MH, Tuvshintur B, Kim WJ, et al. Expression of the apelin-APJ pathway and effects on erectile function in a mouse model of vasculogenic erectile dysfunction. Journal of Sexual Medicine. 2013; 10: 2928-2941. Go to original source... Go to PubMed...
    42. Ryu JK, Han JY, Chu YC, et al. Expression of cavernous transforming growth factor-beta1 and its type II receptor in patients with erectile dysfunction. International Journal of Andrology. 2004; 27: 42-49. Go to original source... Go to PubMed...
    43. Song KM, Chung JS, Choi MJ, et al. Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in a mouse model of cavernous nerve injury. Journal of Sexual Medicine. 2014; 11: 51-63. Go to original source... Go to PubMed...
    44. Li WJ, Wang H, Zhou J, et al. P144, a TGF-?1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats. Journal of Sexual Medicine. 2013; 10: 2942-2951. Go to original source... Go to PubMed...
    45. Lu Z, Lin G, Reed-Maldonado A. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. European Urology. 2016; 71: 223-233. Go to original source... Go to PubMed...
    46. Li H, Matheu MP, Sun F. Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model. Translational Andrology and Urology. 2016; 5: 977-979. Go to original source... Go to PubMed...
    47. Fojecki GL, Tiessen S, Osther PJS. Effect of Linear Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction - 12-Month Follow-Up of a Randomized, Double-Blinded, Sham-Controlled Study. Sexual Medicine. 201; 6(1): 1-7.
    48. Clavijo RI, Kohn TP, Kohn JR. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. Journal of Sexual Medicine. 2017; 14: 27-35. Go to original source... Go to PubMed...
    49. Angulo JC, Arance I, de Las Heras MM, Meilán E, Esquinas C, Andrés EM. Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. Actas Urológicas Espa?olas. October 2017; 41(8): 479-490. Go to original source...
    50. Wang TD, Lee WJ, Yang SC, Lin PC, Tai HC, Liu SP, et al. Clinical and Imaging Outcomes up to 1 Year Following Balloon Angioplasty for Isolated Penile Artery Stenoses in Patients With Erectile Dysfunction: The PERFECT-2 Study. Journal of Endovascular Therapy. 14. September 2016. Go to original source... Go to PubMed...
    51. Sohn M, Hatzinger M, Goldstein I, Krishnamurti S. Standard operating procedures for vascular surgery in erectile dysfunction: revascularization and venous procedures. Journal of Sexual Medicine. 2013; 10(1): 172-179. Go to original source... Go to PubMed...
    52. Hellstrom WJ, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. Journal of Sexual Medicine. 2010; 7: 501. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.